riluzole has been researched along with Schizophrenia in 4 studies
Riluzole: A glutamate antagonist (RECEPTORS, GLUTAMATE) used as an anticonvulsant (ANTICONVULSANTS) and to prolong the survival of patients with AMYOTROPHIC LATERAL SCLEROSIS.
Schizophrenia: A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We aimed to assess the efficacy and tolerability of riluzole, an anti-glutamate agent with neuroprotective properties, as an adjunct to risperidone in improving negative symptoms of schizophrenia." | 9.19 | A double-blind, placebo controlled, randomized trial of riluzole as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia. ( Akhondzadeh, S; Farokhnia, M; Hosseini, SM; Khodaie-Ardakani, MR; Pourmahmoud, H; Rezaei, F; Sabzabadi, M; Salehi, B; Tabrizi, M; Yekehtaz, H, 2014) |
| "We aimed to assess the efficacy and tolerability of riluzole, an anti-glutamate agent with neuroprotective properties, as an adjunct to risperidone in improving negative symptoms of schizophrenia." | 5.19 | A double-blind, placebo controlled, randomized trial of riluzole as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia. ( Akhondzadeh, S; Farokhnia, M; Hosseini, SM; Khodaie-Ardakani, MR; Pourmahmoud, H; Rezaei, F; Sabzabadi, M; Salehi, B; Tabrizi, M; Yekehtaz, H, 2014) |
| " We evaluated the evidence from randomized controlled trials (RCTs) regarding the use of the glutamatergic drug riluzole in mental illnesses; and conducted preliminary meta-analyses of its effectiveness in treating obsessive-compulsive disorder (OCD) and depression." | 5.01 | Efficacy and tolerability of riluzole in psychiatric disorders: A systematic review and preliminary meta-analysis. ( Amelsvoort, TV; de Boer, JN; Hirdes, M; McAlonan, GM; Vingerhoets, C; Zinkstok, JR, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Loveland, P | 1 |
| Wong, A | 1 |
| Vivekanandam, V | 1 |
| Lim, WK | 1 |
| Pillinger, T | 1 |
| Rogdaki, M | 1 |
| McCutcheon, RA | 1 |
| Hathway, P | 1 |
| Egerton, A | 1 |
| Howes, OD | 1 |
| de Boer, JN | 1 |
| Vingerhoets, C | 1 |
| Hirdes, M | 1 |
| McAlonan, GM | 1 |
| Amelsvoort, TV | 1 |
| Zinkstok, JR | 1 |
| Farokhnia, M | 1 |
| Sabzabadi, M | 1 |
| Pourmahmoud, H | 1 |
| Khodaie-Ardakani, MR | 1 |
| Hosseini, SM | 1 |
| Yekehtaz, H | 1 |
| Tabrizi, M | 1 |
| Rezaei, F | 1 |
| Salehi, B | 1 |
| Akhondzadeh, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Dextromethorphan as an Augmentation Agent in Treatment-resistant Schizophrenia: A Randomized, Group Sequential Adaptive Design, Controlled Clinical Trial[NCT05944510] | Phase 4 | 72 participants (Anticipated) | Interventional | 2023-08-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for riluzole and Schizophrenia
| Article | Year |
|---|---|
Efficacy and tolerability of riluzole in psychiatric disorders: A systematic review and preliminary meta-analysis.
Topics: Adult; Autistic Disorder; Depressive Disorder; Female; Humans; Male; Mental Disorders; Neuroprotecti | 2019 |
1 trial available for riluzole and Schizophrenia
| Article | Year |
|---|---|
A double-blind, placebo controlled, randomized trial of riluzole as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Double-Blind Method; Drug Therapy, Combination; Excita | 2014 |
2 other studies available for riluzole and Schizophrenia
| Article | Year |
|---|---|
Subacute combined degeneration of the spinal cord masking motor neuron disease: a case report.
Topics: Comorbidity; Confusion; Diagnosis, Differential; Disease Progression; Dysarthria; Electromyography; | 2019 |
Altered glutamatergic response and functional connectivity in treatment resistant schizophrenia: the effect of riluzole and therapeutic implications.
Topics: Adult; Cerebrovascular Circulation; Excitatory Amino Acid Antagonists; Female; Glutamic Acid; Gyrus | 2019 |